HAVE ANY QUESTIONS? CLICK HERE
BIOMATLANTE announces the appointment of its new CEO
- Biomatlante News
Julien Dert named as new CEO of Biomatlante, Chantal Gobin continues as Chairman of the Board
Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the appointment of its new CEO, Julien Dert, being effective on February 1st, 2019.
Clinical Performance of hydrogel- bioceramic Putty for Bone Regeneration in maxillofacial surgery
- Biomatlante News
The article shows the valorization of results of a non interventional clinical study of 78 patients with the product In’Oss™ in association with a collagen resorbable membrane in maxillofacial surgery. The safety and efficacy of In’Oss has been demonstrated, as well as the performance of EZ Cure membrane associated to it.
Variation of bone forming ability with the physicochemical properties of calcium phosphate bone substitutes
- Biomatlante News
Six commercially available CaP bone substitutes (Bio-Oss, Actifuse, Bi-Ostetic, MBCP, Vitoss and chronOs) as well as two tricalcium phosphate (TCP) ceramics with either a micron-scale (TCP-B) or submicronscale (TCP-S) surface structure are characterized and their bone forming potential is evaluated in a canine ectopic implantation model.
MBCP+™, the adapted matrix for tissue engineering
- Biomatlante News
After the success of the European program REBORNE (FP7) focused on safety and efficacy of the Biomatlante matrix combined with autologous bone marrow expanded mesenchymal stem cells (MSC), MBCP+™, made from our well-known MBCP Technology, was confirmed as the adapted matrix for tissue engineering and chosen for 2 new European research programs (H2020): MAXIBONE and ORTHOUNION.
Coordinated by INSERM (Institut National de la Santé et de la Recherche Médicale) and with the support of the E.U., the REBORNE Program sought to establish the feasibility, relevance and efficacy of the association of MBCP+™*, a synthetic bone graft manufactured by Biomatlante made from MBCP™ Technology, and Mesenchymal Stem Cells (MSCs)1.
Introduction: Bone is the most transplanted tissue in human with about 1 million procedures annually in Europe. Autologous bone grafting is the gold standard in bone regeneration but it requires a second surgery, is limited in quantity and often associated with painful complications. Synthetic calcium phosphate biomaterial in association with mesenchymal stem cells may be a potent alternative to autologous bone grafting.
Biomatlante, has been at the forefront of development of new synthetic bone graft.
5 Rue Edouard Belin, 44360 Vigneux-de-Bretagne, France
+33 2 28 02 00 09
Contact@biomatlante.com
5 Rue Edouard Belin, 44360 Vigneux-de-Bretagne, France
+33 2 28 02 00 09
Contact@biomatlante.com